Oncolytics Biotech (NASDAQ:ONCY) Shares Up 1.9%

Oncolytics Biotech Inc. (NASDAQ:ONCY)’s stock price shot up 1.9% during mid-day trading on Thursday . The stock traded as high as $1.12 and last traded at $1.08. 302,083 shares were traded during trading, a decline of 18% from the average session volume of 369,111 shares. The stock had previously closed at $1.06.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Raymond James started coverage on Oncolytics Biotech in a research note on Thursday, April 4th. They issued an “outperform” rating and a $3.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Wednesday, February 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Oncolytics Biotech in a research note on Friday, January 12th.

Oncolytics Biotech Trading Up 1.9 %

The stock has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.28. The company has a market cap of $81.45 million, a price-to-earnings ratio of -3.60 and a beta of 1.93.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. As a group, research analysts forecast that Oncolytics Biotech Inc. will post -0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONCY. Ausdal Financial Partners Inc. lifted its holdings in Oncolytics Biotech by 50.0% in the fourth quarter. Ausdal Financial Partners Inc. now owns 30,000 shares of the company’s stock valued at $40,000 after acquiring an additional 10,000 shares during the period. Advisor Resource Council acquired a new position in shares of Oncolytics Biotech in the 4th quarter valued at $135,000. Finally, International Assets Investment Management LLC boosted its holdings in Oncolytics Biotech by 33.9% during the fourth quarter. International Assets Investment Management LLC now owns 269,699 shares of the company’s stock worth $364,000 after buying an additional 68,246 shares in the last quarter. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.